| Title |
The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, July 2007
|
| DOI | 10.1007/s10549-007-9679-4 |
| Pubmed ID | |
| Authors |
Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Yasuo Ohashi, Kiichiro Tsutani |
| Abstract |
Several randomized controlled trials have confirmed the usefulness of trastuzumab as an adjuvant therapy for HER2-overexpressed breast cancer patients; however, the costs for 1-year treatment are high. Therefore, we performed an economic analysis regarding the efficient distribution of medical resources. |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 4% |
| United Kingdom | 1 | 2% |
| Unknown | 43 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 26% |
| Researcher | 8 | 17% |
| Student > Ph. D. Student | 6 | 13% |
| Student > Doctoral Student | 3 | 7% |
| Professor | 3 | 7% |
| Other | 6 | 13% |
| Unknown | 8 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 17% |
| Economics, Econometrics and Finance | 5 | 11% |
| Psychology | 3 | 7% |
| Business, Management and Accounting | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 12 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2012.
All research outputs
#4,689,563
of 22,757,090 outputs
Outputs from Breast Cancer Research and Treatment
#886
of 4,652 outputs
Outputs of similar age
#13,032
of 67,127 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#9
of 30 outputs
Altmetric has tracked 22,757,090 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,652 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 67,127 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.